Literature DB >> 8621397

Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase.

S M Cutts1, P G Parsons, R A Sturm, D R Phillips.   

Abstract

Adriamycin is known to specifically induce DNA interstrand cross-links at 5'-GC sequences. Because 5'-GC sequences are a predominant feature of 5'-untranslated regions (transcription factor-binding sites, promoter, and enhancer regions), it is likely that adriamycin adducts at GC sites would affect the binding of DNA-interacting proteins. Two model systems were chosen for the analysis: the octamer-binding proteins Oct-1, N-Oct-3 and N-Oct-5, which bind to ATGCAAAT and TAATGARAT recognition sites, and Escherichia coli RNA polymerase binding to the lac UV5 promoter. Electrophoretic mobility shift studies showed that adriamycin adducts at GC sites inhibited the binding of octamer proteins to their consensus motifs at drug levels as low as 1 micoM, but no effect was observed with a control sequence lacking a GC site. Adriamycin adducts at GC sites also inhibited the binding of RNA polymerase to the lac UV5 promoter. Adriamycin may therefore function by down-regulating the expression of specific genes by means of inactivation of short but critical motifs containing one or more GC sites.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621397     DOI: 10.1074/jbc.271.10.5422

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

Review 1.  Chemical approaches to control gene expression.

Authors:  J M Gottesfeld; J M Turner; P B Dervan
Journal:  Gene Expr       Date:  2000

2.  Molecular mechanisms by which white tea prevents oxidative stress.

Authors:  C Espinosa; F Pérez-Llamas; F A Guardiola; M A Esteban; M B Arnao; S Zamora; J A López-Jiménez
Journal:  J Physiol Biochem       Date:  2014-09-26       Impact factor: 4.158

3.  Analysis of proteome changes in doxorubicin-treated adult rat cardiomyocyte.

Authors:  Suresh N Kumar; Eugene A Konorev; Deepika Aggarwal; Balaraman Kalyanaraman
Journal:  J Proteomics       Date:  2011-02-19       Impact factor: 4.044

Review 4.  Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.

Authors:  Rachel E Nicoletto; Clyde M Ofner
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-12       Impact factor: 3.333

5.  Activation of microbubbles by low-level therapeutic ultrasound enhances the antitumor effects of doxorubicin.

Authors:  Shuang Yang; Pan Wang; Xiaobing Wang; Xiaomin Su; Quanhong Liu
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

6.  IS METABOLIC ACTIVATION OF TOPOISOMERASE II POISONS IMPORTANT IN THE MECHANISM OF CYTOTOXICITY?

Authors:  Birandra K Sinha; Ronald P Mason
Journal:  J Drug Metab Toxicol       Date:  2015-07-24

7.  Inhibition of glycolysis disrupts cellular antioxidant defense and sensitizes HepG2 cells to doxorubicin treatment.

Authors:  Agnieszka Korga; Marta Ostrowska; Magdalena Iwan; Mariola Herbet; Jaroslaw Dudka
Journal:  FEBS Open Bio       Date:  2019-04-11       Impact factor: 2.693

Review 8.  HSP27 role in cardioprotection by modulating chemotherapeutic doxorubicin-induced cell death.

Authors:  Sivasubramanian Ramani; Sungkwon Park
Journal:  J Mol Med (Berl)       Date:  2021-03-16       Impact factor: 4.599

9.  Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae.

Authors:  Tammy J Westmoreland; Sajith M Wickramasekara; Andrew Y Guo; Alice L Selim; Tiffany S Winsor; Arno L Greenleaf; Kimberly L Blackwell; John A Olson; Jeffrey R Marks; Craig B Bennett
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

10.  The Product of Matrix Metalloproteinase Cleavage of Doxorubicin Conjugate for Anticancer Drug Delivery: Calorimetric, Spectroscopic, and Molecular Dynamics Studies on Peptide-Doxorubicin Binding to DNA.

Authors:  Kamila Butowska; Krzysztof Żamojć; Mateusz Kogut; Witold Kozak; Dariusz Wyrzykowski; Wiesław Wiczk; Jacek Czub; Jacek Piosik; Janusz Rak
Journal:  Int J Mol Sci       Date:  2020-09-21       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.